Search

Your search keyword '"Betjes, M. G.H."' showing total 16 results
Start Over Author "Betjes, M. G.H."
16 results on '"Betjes, M. G.H."'

1. Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations in kidney transplant recipients:Results from a randomized controlled study

Author

Fatly, Z. Al, Betjes, M. G.H., Dik, W. A., Fouchier, R. A.M., Reinders, M. E.J., de Weerd, A. E., Fatly, Z. Al, Betjes, M. G.H., Dik, W. A., Fouchier, R. A.M., Reinders, M. E.J., and de Weerd, A. E.

Abstract

Objectives: To study the effect of mycophenolate mofetil (MMF) on various vaccination responses in kidney transplant recipients. Methods: In a randomized controlled trial (EudraCT nr.: 2014-001372-66), low immunologically risk kidney transplant recipients were randomized to TAC/MMF or TAC-monotherapy (TACmono), six months post-transplantation. One year after transplantation, in a pre-specified sub-study, recipients were vaccinated against pneumococcus, tetanus and influenza. Blood was sampled before and 21 days after vaccination. Adequate vaccination responses were defined by international criteria. A post-hoc analysis was conducted on SARS-CoV-2 vaccination responses within the same cohort. Results: Seventy-one recipients received pneumococcal and tetanus vaccines (TAC/MMF: n = 37, TACmono: n = 34), with 29 also vaccinated against influenza. When vaccinated, recipients were 60 (54–66) years old, with median eGFR of 54 (44–67) ml/min, tacrolimus trough levels 6.1 (5.4–7.0) ug/L in both groups and TAC/MMF daily MMF dose of 1000 (500–2000) mg. Adequate vaccination responses were: pneumococcal (TAC/MMF 43%, TACmono 74%, p = 0.016), tetanus (TAC/MMF 35%, TACmono 82%, p < 0.0001) and influenza (TAC/MMF 20%, TACmono 71%, p = 0.0092). Only 7% of TAC/MMF responded adequately to all three compared to 36% of TACmono (p = 0.080). Additionally, 40% of TAC/MMF responded inadequately to all three, whereas all TACmono patients responded adequately to at least one vaccination (p = 0.041). Lower SARS-CoV-2 vaccination antibody responses correlated with lower pneumococcal antibody vaccination responses (correlation coefficient: 0.41, p = 0.040). Conclusions: MMF on top of tacrolimus severely hampers antibody responses to a broad range of vaccinations.

Published
2024

2. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

Author

de Boer, S. E., Sanders, J. S.F., Bemelman, F. J., Betjes, M. G.H., Burgerhof, J. G.M., Hilbrands, L., Kuypers, D., van Munster, B. C., Nurmohamed, S. A., de Vries, A. P.J., van Zuilen, A. D., Hesselink, D. A., and Berger, S. P.

Published
2021
Full Text
View/download PDF

3. Additional file 1 of Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

Author

de Boer, S. E., Sanders, J. S.F., Bemelman, F. J., Betjes, M. G.H., Burgerhof, J. G.M., Hilbrands, L., Kuypers, D., van Munster, B. C., Nurmohamed, S. A., de Vries, A. P.J., van Zuilen, A. D., Hesselink, D. A., and Berger, S. P.

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2021
Full Text
View/download PDF

4. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author

Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.

Published
2018

5. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant

Author

CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Mondziekten/Kaakchirurgie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., Otten, H. G., CTI Otten, Infection & Immunity, CDL Celdiagnostiek, CTI, MS Nefrologie, Circulatory Health, Nefro Vasculaire Geneeskunde, Regenerative Medicine and Stem Cells, Cardiovasculaire Epi Team 5, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Mondziekten/Kaakchirurgie, Kamburova, E. G., Wisse, B. W., Joosten, I., Allebes, W. A., van der Meer, A., Hilbrands, L. B., Baas, M. C., Spierings, E., Hack, C. E., van Reekum, F. E., van Zuilen, A. D., Verhaar, M. C., Bots, M. L., Drop, A. C.A.D., Plaisier, L., Seelen, M. A.J., Sanders, J. S.F., Hepkema, B. G., Lambeck, A. J.A., Bungener, L. B., Roozendaal, C., Tilanus, M. G.J., Voorter, C. E., Wieten, L., van Duijnhoven, E. M., Gelens, M., Christiaans, M. H.L., van Ittersum, F. J., Nurmohamed, S. A., Lardy, N. M., Swelsen, W., van der Pant, K. A., van der Weerd, N. C., ten Berge, I. J.M., Bemelman, F. J., Hoitsma, A., van der Boog, P. J.M., de Fijter, J. W., Betjes, M. G.H., Heidt, S., Roelen, D. L., Claas, F. H., and Otten, H. G.

Published
2018

6. The truth on current peritoneal dialysis:State of the art

Author

Krediet, R. T., Abrahams, A. C., de Fijter, C. W.H., Betjes, M. G.H., Boer, W. H., van Jaarsveld, B. C., Konings, C. J.A.M., and Dekker, F. W.

Abstract

The share of peritoneal dialysis (PD) in the spectrum of chronic dialysis has decreased markedly in the Netherlands in the last 15 years. Consequently, the knowledge of nephrologists and nursing staff on PD has declined leading to a negative spiral in which loss of experience resulted in loss of enthusiasm to offer PD to patients and also in less interest in the new PD developments. All these changes took place while the results of PD improved and patient survival was at least similar to that on haemodialysis. The aim of this review is first to give a summary of the principles and practice of patient and staff education and to describe the role of the medical contribution in decision-making. On this basis, the second aim is to update internist-nephrologists on a number of issues that have been underexposed in the past. Recent patient and technique survival data of PD patients is reviewed, and also the new insights into dialysis adequacy. The presence of residual renal function is the main determinant of patient survival together with prevention of overhydration. Urea and creatinine removal are not important at all when patients are still passing urine. Many early problems with PD are due to the peritoneal catheter and suggestions are made for improvement of its function. The prevention and management of infections is reviewed, and also the regular assessment of peritoneal function. Free water transport is a predictor of encapsulating peritoneal sclerosis (EPS), which should be assessed regularly. The pathogenesis of EPS, treatment and the decreasing incidence are discussed.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results